Angela Mastronuzzi: GD2-Targeting CAR T Cells in High-Risk Neuroblastoma
Angela Mastronuzzi, Head of Neuro-Oncology Unit at Bambino Gesù Children’s Hospital and President of AIEOP, shared a post on LinkedIn:
“Just published! GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial
- Antidisialoganglioside (GD2), third-generation chimeric antigen receptor (CAR) T cells (GD2–CART01) have shown encouraging efficacy in children with high-risk metastatic, relapsed, or refractory neuroblastoma in the interim analysis of a phase 1/phase 2 clinical trial.
- We present the final results obtained in all 35 patients enrolled and in 19 additional children selected with the same criteria of the trial and treated in a hospital exemption setting.”
Title: GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial
Authors: Franco Locatelli, Daria Pagliara, Maria A. De Ioris, Marco Becilli, Giada Del Baldo, Annalisa Serra, Angela Mastronuzzi, Maria G. Cefalo, Giuseppina Li Pira, Giovanna Leone, Valentina Bertaina, Francesco Fabozzi, Matteo Di Nardo, Chiara Rosignoli, Maria Luisa D’Andrea, Alessandro Crocoli, Sabina Vennarini, Matilde Sinibaldi, Stefano Di Cecca, Marika Guercio, Laura Iaffaldano, Barbarella Lucarelli, Mattia Algeri, Pietro Merli, Francesca del Bufalo
Readthe Full Article.
More posts featuring Angela Mastronuzzi on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023